{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:03:18Z","timestamp":1768208598958,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Abbvie GK and Eisai co. ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s12325-018-0866-y","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T11:02:30Z","timestamp":1547895750000},"page":"691-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis"],"prefix":"10.1007","volume":"36","author":[{"given":"Hidemi","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawaberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"866_CR1","doi-asserted-by":"publisher","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20132011. PLoS One. 2012;7:e52935.","journal-title":"PLoS One"},{"key":"866_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:2095\u20136.","journal-title":"N Engl J Med"},{"key":"866_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","volume":"51","author":"W Tillett","year":"2012","unstructured":"Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51:275\u201383.","journal-title":"Rheumatology (Oxford)"},{"key":"866_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","volume":"22","author":"DD Gladman","year":"2009","unstructured":"Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40\u201355.","journal-title":"Dermatol Ther"},{"key":"866_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/j.1346-8138.2010.01145.x","volume":"38","author":"H Takahashi","year":"2011","unstructured":"Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H, Japanese Society for Psoriasis Research. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol. 2011;38:1125\u20139.","journal-title":"J Dermatol"},{"key":"866_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/1346-8138.13342","volume":"43","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Ohtsuki M, Sano S, et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016;43:1193\u20136.","journal-title":"J Dermatol"},{"key":"866_CR7","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1111\/1346-8138.13800","volume":"44","author":"T Yamamoto","year":"2017","unstructured":"Yamamoto T, Ohtsuki M, Sano S, et al. Prevalence and current therapies of psoriatic arthritis in Japan: a survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol. 2017;44:e121.","journal-title":"J Dermatol"},{"key":"866_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/1346-8138.14097","volume":"45","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto T, Kawada A. Clinical characteristics of Japanese patients with psoriatic arthritis: comparison with East Asian countries. J Dermatol. 2018;45:273\u20138.","journal-title":"J Dermatol"},{"key":"866_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jdermsci.2013.06.003","volume":"72","author":"M Hayashi","year":"2013","unstructured":"Hayashi M, Saeki H, Ito T, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with psoriasis. J Dermatol Sci. 2013;72:188\u201391.","journal-title":"J Dermatol Sci"},{"key":"866_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"866_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/1346-8138.12239","volume":"40","author":"M Ohtsuki","year":"2013","unstructured":"Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40:683\u201395.","journal-title":"J Dermatol"},{"key":"866_CR12","unstructured":"Products Approved in FY 2009: New drugs: pharmaceuticals and Medical Devices Agency, Japan. 2009. https:\/\/www.pmda.go.jp\/files\/000153452.pdf. Accessed 6 June 2018."},{"key":"866_CR13","unstructured":"HUMIRA\u00ae Package Insert (in Japanese) Pharmaceuticals and Medical Devices Agency, Japan. 2018. http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/112130_3999426G2020_1_03.pdf. Accessed 2 Oct 2018."},{"key":"866_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","volume":"37","author":"A Asahina","year":"2010","unstructured":"Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study. J Dermatol. 2010;37:299\u2013310.","journal-title":"J Dermatol"},{"key":"866_CR15","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","volume":"66","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66:e67\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"866_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/1346-8138.13409","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina A, Torii H, Ohtsuki M, et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016;43:1257\u201366.","journal-title":"J Dermatol"},{"key":"866_CR17","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"866_CR18","unstructured":"WPAI:SHP V2.0: Reilly Associates; updated August 18, 2010. http:\/\/www.reillyassociates.net\/WPAI_SHP.html. Accessed 24 Apr 2018."},{"key":"866_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12325-017-0477-z","volume":"34","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Nakajima R, Komatsu S, et al. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv Ther. 2017;34:686\u2013702.","journal-title":"Adv Ther"},{"key":"866_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"866_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","volume":"63","author":"A Menter","year":"2010","unstructured":"Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"866_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/1346-8138.13001","volume":"42","author":"A Asahina","year":"2015","unstructured":"Asahina A, Ohtsuki M, Etoh T, et al. Adalimumab treatment optimization for psoriasis: results of a long-term phase 2\/3 Japanese study. J Dermatol. 2015;42:1042\u201352.","journal-title":"J Dermatol"},{"key":"866_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MN Di Minno","year":"2014","unstructured":"Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis. 2014;73:1157\u201362.","journal-title":"Ann Rheum Dis"},{"key":"866_CR24","first-page":"603","volume":"56","author":"W Tillett","year":"2017","unstructured":"Tillett W, Shaddick G, Jobling A, et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford). 2017;56:603\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"866_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2217\/cer-2016-0020","volume":"5","author":"S Sz\u00e1nt\u00f3","year":"2016","unstructured":"Sz\u00e1nt\u00f3 S, Po\u00f3r G, Opris D, et al. Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe. J Comp Eff Res. 2016;5:475\u201385.","journal-title":"J Comp Eff Res"},{"key":"866_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3899\/jrheum.170874","volume":"45","author":"N Iragorri","year":"2018","unstructured":"Iragorri N, Hofmeister M, Spackman E, Hazlewood GS. The effect of biologic and targeted synthetic drugs on work- and productivity-related outcomes for patients with psoriatic arthritis: a systematic review. J Rheumatol. 2018;45:1124\u201330.","journal-title":"J Rheumatol"},{"key":"866_CR27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u201389.","journal-title":"Arthritis Rheum"},{"key":"866_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41:514\u201321.","journal-title":"Clin Exp Dermatol"},{"key":"866_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/rheumatology\/keu264","volume":"54","author":"W Tillett","year":"2015","unstructured":"Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157\u201362.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0866-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:07:25Z","timestamp":1713809245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0866-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0866-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}